Yasuhiro Imaeda

This inventor holds 12 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2010-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yasuhiro Imaeda. Retrieved from https://idiyas.com/inventor/yasuhiro-imaeda

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 12 (Patent Applications = 3)

% Patents Active = 50.0

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 4 (Patent Applications = 6)

Average Co-Inventor Count = 4.5

ph-index = 2

Forward Citations = 13(Granted Patents)

Location History:

Osaka, JP (2010 - 2014)
Ann Arbor, MI (US) (2012 - 2015)
Kanagawa, JP (2014 - 2024)

Company Filing History:

12 out of 1,229

Takeda Pharmaceutical Company Limited

patents

Years Active: 2010-2025

Loading Chart...

12 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12435063 - Nitrogen containing heterocycles as CDK12 inhibitors (2025-10-07),

2. 12084436 - Heterocyclic compound (2024-09-10),

3. 11584737 - Heterocyclic compound (2023-02-21),

4. 10435399 - HDAC6 inhibitory heterocyclic compound (2019-10-08),

5. 9221836 - Heterocyclic compound and use thereof (2015-12-29),

6. 9045436 - Heterocyclic compound and use thereof (2015-06-02),

7. 8697865 - Cyclic amide derivative, and its production and use (2014-04-15),

8. 8664380 - Heterocyclic compound and use thereof (2014-03-04),

9. 8466282 - Heterocyclic compound and use thereof (2013-06-18),

10. 8329691 - Amide compounds and use of the same (2012-12-11),

11. 7820673 - Urea derivative, process for producing the same, and use (2010-10-26),

12. 7745623 - Cyclic amide derivative, and its production and use (2010-06-29),

Title: The Innovations of Yasuhiro Imaeda: Pioneering Advances in Pharmaceutical Chemistry

Introduction

Yasuhiro Imaeda, an accomplished inventor based in Kanagawa, Japan, has made significant contributions to the field of pharmaceutical chemistry through his innovative work. With a remarkable portfolio of 11 patents, Imaeda specializes in developing compounds that aim to provide therapeutic solutions for various medical conditions, particularly in the realm of central nervous system diseases and cancer.

Latest Patents

Among his most recent inventions, Imaeda has developed a heterocyclic compound that exhibits HDAC inhibitory action. This compound is poised to play a crucial role in treating central nervous system diseases, including neurodegenerative disorders. Additionally, Imaeda has created another heterocyclic compound believed to have superior CDK12 inhibitory action, which is anticipated to be beneficial as a prophylactic or therapeutic drug for cancer. The details of these inventions are captured in the formulas specified in his patent descriptions.

Career Highlights

Yasuhiro Imaeda is currently affiliated with Takeda Pharmaceutical Company Limited, a leading global pharmaceutical company. His work at Takeda underscores his commitment to advancing healthcare through research and innovation. Imaeda's contributions are pivotal in enhancing the company's portfolio of therapeutic solutions.

Collaborations

Throughout his career, Imaeda has collaborated with esteemed colleagues such as Takanobu Kuroita and Hidekazu Tokuhara. These partnerships have likely enriched his research endeavors, fostering a collaborative environment that stimulates innovation and accelerates the development of life-changing compounds.

Conclusion

Yasuhiro Imaeda's inventive spirit and dedication to pharmaceutical advancements have positioned him as a notable figure in his field. His ongoing efforts in drug development not only reflect his expertise but also offer hope for addressing critical health challenges. As he continues to innovate, the impact of his work is sure to resonate within the medical community and beyond.

Profile summary based on public USPTO records.